Pharmacological considerations in high-dose chemotherapy

Cancer Chemotherapy and Pharmacology, Supplement

Volumn 40, Issue , 1997, Pages

  Sasaki, Yasutsuna ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

High dose chemotherapy; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER; CHEMOTHERAPY; CONFERENCE PAPER; DOSE RESPONSE; DRUG EXPOSURE; HUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0030740650     PISSN: 09439404     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800051073     Document Type: Conference Paper

References (18)

1. Anderson LW, Chen TL, Colvin OM, Grochow LB, Collins JM, Kennedy J, Strong JM (1996) Cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy. Clin Cancer Res 2:1481
2. Antman K, Ayashi L, Elias A, Wheeler C, Hunt M, Eder JP, Teicher BA, Critchow J, Bibbo J, Schnipper LE, Frei E III (1992) A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102
3. Canal P, Attal M, Chatelut E, Guichard S, Huguest F, Muller C, Schlaifer D, Laurent G, Houin G, Bugat R (1993) Plasma and cellular pharmacokinetics of mitoxantrone in high-dose chemotherapeutic regimen for refractory lymphomas. Cancer Res 53:4850
4. Chen TL, Passos-Coelho JL, Noe DA, Kennedy MJ, Black KC, Colvin OM, Grochow LB (1995) Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res 55:810
5. Frei E III (1992) Pharmacologic strategies for high-dose chemotherapy. In: Armitage JO, Antmann KH (eds) High-dose cancer therapy: pharmacology, hematopoietines, stem cells. Williams & Wilkins, Baltimore, pp 1-13
6. Frei E III, Canellos G (1980) Dose: a critical factor in cancer chemotherapy. Am J Med 69:585
7. Frei E III, Cucchi CA, Rosowsky A, Tantravahi R, Bernal S, Ervin TJ, Ruprecht RM, Haseltine WA (1985) Alkylating agent resistance: in vitro studies with human cell lines. Proc Natl Acad Sci USA 82:2158
8. Gianni L, Kearns CM, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G, Egorin MJ (1995) Non linear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationship in humans. J Clin Oncol 13:180
9. Grochow LB, Krivit W, Whiteley CB, Blazar B (1990) Busulfan disposition in children. Blood 75:1723
10. Henner WD, Schea TC, Furlong EA, Flaherty MD, Eder P, Elias A, Begg C, Antman K (1987) Pharmacokinetics of continuous-infusion high-dose thiotepa. Cancer Treat Rep 71:1043
11. Hryniuk W, Bush H (1984) The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281
12. Jones RB, Matthes S, Shpall EJ, Fisher JK, Stemmer SM, Dufton C, Stephens JK, Bearman SI (1993) Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine. J Natl Cancer Inst 85:640
13. Kennedy MJ, Armstrong DK, Huelskamp AM, Ohly K, Clarke BV, Colvin OM, Grochow LB, Chen TL, Davidson NE (1995) Phase I and pharmacologic study of the alkylating agent modulator novo-biocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer. J Clin Oncol 13:1136
14. Ohtu T, Sasaki Y, Tamura T, Miyata Y, Nakanomyo H, Nishiwaki Y, Saijo N (1995) Clinical pharmacokinetics and pharmacodynamics of paclitaxel: a 3-hour infusion versus a 24-hour infusion. Clin Cancer Res 1:599
15. Peters WP, Ross M, Vredenburgh JJ, Meisenburg B, Marks LB, Winer E, Kurtzberg J, Bast RC, Jones R Jr, Shpall ES, Wu K, Rosner G, Gilbert C, Mathias B, Coniglio D, Petros W, Henderson IC, Norton L, Weiss RB, Budman D, Hurd D (1993) High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132
16. Stemmer SM, Cagnori PJ, Shpall EJ, Bearman SI, Matthes S, Dufton C, Day T, Taffs S, Hami L, Martinez C, Purdy MH, Arron J, Jones RB (1996) High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol 14:1463
17. Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A, Lamerle J, Gouyette A, Hartmann O (1995) Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 37:247
18. Warmerdam LC van, Rodenhuis SR, Wall E van der, Maes RAA, Beijnen LH (1996) Pharmacokinetics and pharmacodynamics of carboplatin in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem-cell support. Br J Cancer 73:979